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BACKGROUND AND PURPOSE
Ionotropic GABA receptors are evolutionarily conserved proteins that mediate cellular and network inhibition in both vertebrates
and invertebrates. A unique class of excitatory GABA receptors has been identified in several nematode species. Despite well-
characterized functions in Caenorhabditis elegans, little is known about the pharmacology of the excitatory GABA receptors EXP-1
and LGC-35. Using a panel of compounds that differentially activate and modulate ionotropic GABA receptors, we investigated
the agonist binding site and allosteric modulation of EXP-1 and LGC-35.
EXPERIMENTAL APPROACH
We used two-electrode voltage clamp recordings to characterize the pharmacological profile of EXP-1 and LGC-35 receptors
expressed in Xenopus laevis oocytes.
KEY RESULTS
The pharmacology of EXP-1 and LGC-35 is different from that of GABAA and GABAA-ρ receptors. Both nematode receptors are
resistant to the competitive orthosteric antagonist bicuculline and to classical ionotropic receptor pore blockers. The GABAA-ρ
specific antagonist, TPMPA, was the only compound tested that potently inhibited EXP-1 and LGC-35. Neurosteroids have
minimal effects on GABA-induced currents, but ethanol selectively potentiates LGC-35.
CONCLUSIONS AND IMPLICATIONS
The pharmacological properties of EXP-1 and LGC-35 more closely resemble the ionotropic GABAA-ρ family. However, EXP-1 and
LGC-35 exhibit a unique profile that differs from vertebrate GABAA and GABAA-ρ receptors, insect GABA receptors and nematode
GABA receptors. As a pair, EXP-1 and LGC-35 may be utilized to further understand the differential molecular mechanisms of
agonist, antagonist and allosteric modulation at ionotropic GABA receptors and may aid in the design of new and more specific
anthelmintics that target GABA neurotransmission.
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Introduction
GABA is the primary fast inhibitory neurotransmitter in both
vertebrate and invertebrate nervous systems (Hosie and
Sattelle, 1996). Fast inhibition is produced when GABA binds
and activates chloride-selective ionotropic GABA receptors.
These receptors belong to the ‘Cys-loop’ superfamily of
ligand-gated ion channels, which include the nicotinic ace-
tylcholine (nAChRs), glycine and 5HT3 receptors (Bormann,
2000). Like all members of the superfamily, ionotropic GABA
receptors consist of five subunits that pseudo-symmetrically
arrange around a central ion-conducting pore (Johnston,
2005). Each subunit consists of a large extracellular
N-terminal domain that contains consensus motifs that
comprise the orthosteric agonist binding site, four
transmembrane-spanning domains (M1–M4) and a large in-
tracellular loop betweenM3 andM4, which is thought to me-
diate receptor trafficking and subcellular localization
(Michels and Moss, 2007; Thompson et al., 2010). Within
the receptor complex, each subunit is arranged such that
the second transmembrane domain (M2) lines the ion chan-
nel pore and determines ion selectivity.
In vertebrates, ionotropic GABA receptors are divided
into two classes based on their distinct oligomerization
and pharmacological profiles: (1) GABAA receptors are
heteropentameric (i.e. multiple different subunits) and
inhibited by the competitive antagonist bicuculline and (2)
GABAA-ρ receptors are homopentameric (i.e. single subunit)
and bicuculline-insensitive (Bormann, 2000; Chebib and
Johnston, 2000). In Caenorhabditis elegans, the ionotropic
GABA receptor family consists of chloride-conducting inhib-
itory (UNC-49) and sodium-conducting excitatory receptors
[expulsion defective (EXP-1) and ligand-gated ion channel
(LGC-35)] (Bamber et al., 1999; Beg and Jorgensen, 2003;
Jobson et al., 2015). Each of these receptors mediate distinct
and coordinated neuromuscular contractions. Specifically,
the inhibitory UNC-49 receptor is required to reciprocally in-
hibit antagonistic body wall muscles to ensure coordinated
locomotion (Bamber et al., 1999); whereas, the excitatory
EXP-1 receptor is required for intestinal muscle contraction
during defecation (Beg and Jorgensen, 2003). Expanding the
unique role of excitatory GABA signalling in the C. elegans
nervous system, LGC-35 was recently shown to act as a spill-
over receptor that modulates locomotor body bending and
movement speed (Jobson et al., 2015).
Although the inhibitory UNC-49 GABA receptor has been
pharmacologically characterized in both free living and
parasitic nematodes (Bamber et al., 2003; Kaji et al., 2015),
relatively little is known about the pharmacological profile
of excitatory GABA receptors in C. elegans. Moreover, excit-
atory GABA receptor signalling not only regulates a wider
variety of neuromuscular contractions that underlie specific
behaviours in the nematode but also utilizes a larger reper-
toire of characterized receptors (EXP-1 and LGC-35). Despite
these observations, canonical inhibitory GABA signalling
and pharmacological profiling of UNC-49 have been the pri-
mary focus of investigation in nematode species.
Here, we have characterized the pharmacological profiles
of EXP-1 and LGC-35 utilizing a broad panel of agonists, an-
tagonists and allosteric modulators that differentially regu-
late ionotropic GABAA and GABAA-ρ receptors. We conclude
that EXP-1 and LGC-35 more closely resemble the GABAA-ρ
receptor subfamily; however, they both exhibit unique
pharmacological profiles despite their highly conserved
orthosteric GABA binding sites. In addition, several charac-
teristics distinguish these receptors from vertebrate GABAA
and GABAA-ρ receptors, insect GABA receptors and nematode
GABA receptors. Taken together, our data reveal that inhibi-
tory and excitatory GABA receptor signalling can be pharma-
cologically segregated, which may aid in the differential and
specific modulation of nematode GABA receptor neurotrans-
mission. Given the high amino acid sequence identity be-
tween EXP-1 and LGC-35, these receptors, as a pair, provide
a useful framework to better understand the differential
mechanisms of agonist, antagonist and allosteric modulation
at ionotropic GABA receptors and may aid in the design of
new and more specific anthelmintic GABA mimetics.
Methods
Animals
All animal care and experimental procedures followed the
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approved by the Institutional Animal Care and Use Commit-
tee (IACUC) at the University of Michigan. Animal studies are
reported in compliance with the ARRIVE guidelines
(Kilkenny et al., 2010; McGrath & Lilley, 2015). X. laevis ova-
ries were obtained from Xenopus1 (Ann Arbor, MI, USA).
Briefly, female X. laevis frogs were housed in a climate-
controlled, light-regulated room. Frogs were anaesthetized by
immersion in 0.2% tricaine until non-responsive to toe pinch.
Subsequently, frogs were decapitated, and ovarian lobes were
harvested and defolliculated by incubation in 2 mg·mL1
collagenase (Type I, Worthington, Lakewood, NJ, USA).
Preparation of receptors
The C. elegans EXP-1 and LGC-35 cDNAs were isolated and
cloned into the X. laevis expression vector pSGEM (cour-
tesy of M. Hollman) as previously described (Beg and
Jorgensen, 2003; Jobson et al., 2015). Briefly, plasmids were
linearized with the restriction enzyme MscI, and capped
RNA (cRNA) was prepared using the mMessage mMachine
kit (Life Technologies) following the manufacturer’s guide-
lines. Defolliculated stages V–VI oocytes were sorted and
injected with EXP-1 (50 ng) or LGC-35 (12.5 ng) cRNA.
Injected oocytes were incubated for 2–5 days at 18°C in
Barth’s solution: 88 mM NaCl, 1 mM KCl, 0.33 mM Ca
(NO3)2, 0.41 mM CaCl2, 0.82 MgSO4, 2.4 mM NaHCO3,
10 mM HEPES, supplemented with 1 mM Na+-pyruvate,
and 50 mg·L1 gentamicin (pH = 7.4, NaOH).
Electrophysiology
Electrophysiological recordings were performed 2–5 days af-
ter injection and were carried out at room temperature in
Ringer’s solution (115 mM NaCl, 2 mM KCl, 1.8 mM CaCl2
and 10 mMHEPES, pH = 7.4 with NaOH). Two electrode volt-
age clamp recordings were obtained using an OC-725C oo-
cyte clamp amplifier (Warner Instruments, Hamden, CT,
USA) using 3 M KCl-filled microelectrodes (1–5 MΩ). All re-
cordings were performed at a holding potential of 60 mV.
Oocytes were exposed to varying concentrations of com-
pounds using a custom-built gravity controlled perfusion
system with a flow rate of ~8 mL·min1. Dose–response
curves were generated on single oocytes by applying com-
pounds at increasing concentrations (low to high). Oocytes
were continually perfused with control Ringer’s for 2 min
between each dose.
Sequence alignments
Protein sequences were aligned using the Clustal W algo-
rithm in the MacVector software suite. The GenBank
identifier numbers for the protein sequences used for
comparative sequence analysis are as follows: EXP-1
(550540762), LGC-35 (71998246), GABRA1 (27808653),
GABRB2 (292495010), GABRG2 (189083762), GABRR1
(223590210) and RDL (635377460).
Homology modelling
The homologymodels of EXP-1 and LGC-35were constructed
based on the crystal structure of the homopentameric
human β3 GABA receptor (PDB ID: 4COF) (Miller and
Aricescu, 2014). The homology models were built using
Modeller 9.17 software (Marti-Renom et al., 2000). An
initial 20 homology models were generated for EXP-1 and
LGC-35, which were then further evaluated with Procheck
software (Laskowski et al., 1996). The model with the lowest
DOPE value and highest LG score was selected for molecular
docking. To compare the differences in ligand binding, GABA
was docked to the crystal structure of the dimeric human
GABA receptor (chain A and B) and the homology models of
EXP-1 and LGC-35 using Autodock Vina software (Trott
and Olson, 2010). The ligand box was centred in the ligand
binding pocket of human GABA receptor with a dimension
of 20 × 24 × 28 Å. The docked results were viewed and
graphed using pymol software (http://www.pymol.org).
Residues were numbered beginning at the start methionine
for each receptor.
Data and statistical analysis
The data and statistical analysis in this study comply with
the recommendations on experimental design and analysis
in pharmacology (Curtis et al., 2015). Data are reported as
mean ± SEM, with n = the number of oocytes recorded and
N = the number of animal replicates. The response of each
compound dose was normalized to the maximal GABA re-
sponse (3 mM) of each individual recorded oocyte. To deter-
mine the overall efficacy of agonists, the maximal response
of each drug tested was normalized relative to the maximal
GABA response (3 mM). Antagonists and allosteric modula-
tor dose–response recordings were performed as follows.
Individual oocytes were exposed to GABA alone (10 μM),
followed by GABA plus increasing concentrations of drug
(10 μM GABA + [Drug]), and control responses were re-tested
at the end of each recording with GABA alone (10 μM)
to confirm complete drug washout and cell health.
Dose–response curves from individual oocytes were nor-
malized to the maximum values and averaged using
Prism 7.0 software (GraphPad, San Diego, CA, USA). Nor-
malized data were fit to the four parameter Hill equation:
Y = Min + (Max  Min)/(1 + 10H(LogEC50  X)),
whereMax is the maximal response,Min is the response at
lowest drug concentration, X is the logarithm of agonist con-
centrations, EC50 is the half-maximal response and H is the
Hill coefficient. Statistical analyses were performed using
Prism 7 (GraphPad, San Diego, CA). One-way ANOVA with
Holm–Sidak post hoc test was used for comparisons involving
more than two groups. Statistical tests with P < 0.05 were
considered significant.
Materials
The following compounds were obtained from Tocris Biosci-
ence (Minneapolis, MN, USA): trans-4-aminocrotonic acid
(TACA); (Z)-3-[(aminoiminomethyl)thio]prop-2-enoic acid
sulfate (ZAPA); 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-
ol hydrochloride (THIP); (1,2,5,6-tetrahydropyridin-4-yl)
methylphosphinic acid (TPMPA); (3α,5α)-3-hydroxypreg-
nane-11,20-dione (alphaxalone); and (3α,5β)-3-hydroxy-
pregnan-20-one (pregnanalone). The following compounds
were obtained from Sigma-Aldrich: GABA; β-alanine;
muscimol), glycine, imidazole-4-acetic acid (IMA);
piperdine-4-sulphonic acid (P4S); 4-piperidinecarboxylic
acid (isonipecotic acid); 5-aminovaleric acid (DAVA);
isoguvacine; bicuculline methchloride, mecamylamine hy-
drochloride and dieldrin. All compound stocks (≥10 mM)
were dissolved in Ringer’s solution and stored at 20°C.
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The water insoluble compounds alphaxalone and
pregnanalone were dissolved in absolute ethanol. Due to
their hydrophobicity, the maximum soluble concentration
of these compounds in Ringer’s solution was 30 μM
(pregnanalone) and 100 μM (alphaxalone).
Results
The C. elegans excitatory GABA receptors EXP-1 and LGC-35
are homopentameric ‘Cys-loop’ ligand gated ion channel
proteins that share 53% identity and 68% similarity across
their entire protein coding sequences. Sequence alignments
against human ionotropic GABAA and GABAA-ρ1 receptor
subunits reveal that EXP-1 and LGC-35 have highly homolo-
gous residues that comprise the orthosteric GABA binding
site (Figure 1A). The neurotransmitters acetylcholine, gly-
cine, serotonin and glutamate exhibit no activity at EXP-1
or LGC-35 when expressed in X. laevis oocytes (Beg and
Jorgensen, 2003; Jobson et al., 2015). Given the specific
GABA-gating, we characterized a broad range of agonists, an-
tagonists and modulators to determine the pharmacological
profiles of EXP-1 and LGC-35 and to functionally classify
the receptor family as GABAA or GABAA-ρ like. We expressed
Figure 1
The orthosteric binding sites of EXP-1 and LGC-35 are highly conserved. (A) Sequence alignment of amino acid motifs (loops A–F) that comprise
the orthosteric GABA binding site. GABA binding occurs at the subunit interface of two adjacent subunits termed the ‘principal’ and ‘complemen-
tary’ subunit. The orthosteric binding site is formed from three loops on the ‘principal’ subunit (loops A–C) and three β-sheets on the ‘complemen-
tary’ subunit (loops D–F). Residue identity is indicated in dark grey and similarity in light grey highlights. Residues involved in ligand binding in this
study are bold-highlighted red (principal), and blue (complementary). Aligned protein sequences, C. elegans EXP-1 and LGC-35, human GABAA
receptor subunits (α1, β2 and γ2) and human GABAA-ρ subunit (ρ1). (B) Structures of known agonists at GABAA receptors that were assayed for
agonist activity at EXP-1 and LGC-35. Compounds that directly activated are categorized as agonists, and those that elicited no activity are cat-
egorized as no response.
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each receptor inX. laevis oocytes and used two-electrode volt-
age clamp to test the concentration–response of a variety of
compounds known to differentially activate, inhibit or mod-
ulate GABAA and GABAA-ρ receptors.
Agonist profiling of EXP-1 and LGC-35
Application of the endogenous neurotransmitter GABA pro-
duced robust and concentration-dependent current re-
sponses with a EC50 value comparable with previously
published data (Figures 2A, 3A and Table 1). Muscimol, a po-
tent orthosteric agonist that differentially activates
ionotropic GABA receptors, is a full agonist at vertebrate
GABAA receptors but only a partial agonist at vertebrate
GABAA-ρ receptors and nematode UNC-49 receptors
(Siddiqui et al., 2010; Johnston, 2014). Dose–response curves
revealed that muscimol exhibited partial agonist activity at
both EXP-1 and LGC-35 with reduced efficacy and potency
compared with GABA, comparable with that observed in
nematode UNC-49 GABA receptors (Siddiqui et al., 2010)
(Figures 2, 3 and Table 1).
GABA is a flexible molecule thought to bind and activate
GABAA receptors in a partially folded conformation
(Krogsgaard-Larsen et al., 2002). Supporting this model, a
number of partially folded conformationally restricted GABA
mimetics are potent agonists at GABAA receptors (Kusama
et al., 1993; Woodward et al., 1993; Hosie and Sattelle,
1996). In contrast, these partially folded analogues are weak
partial agonists or antagonists at GABAA-ρ receptors; whereas,
extended and planar GABA analogues like TACA exhibit high
potency and efficacy at GABAA-ρ receptors (Johnston, 2005).
To classify the agonist profile of EXP-1 and LGC-35, we
determined dose–response relationships using a panel of
conformationally restricted analogues of GABA and
muscimol that show differential potencies and efficacies at
GABAA versus GABAA-ρ receptors (Figure 1B). Known agonists
at GABAA receptors that displayed no current responses at
maximal doses (3 mM) in either EXP-1 or LGC-35 expressing
oocytes were P4S, IMA and THIP. The muscimol analogue
isonipecotic acid (3 mM) showed <5% activity at EXP-1 and
LGC-35 and was not further characterized. Compounds that
exhibited initial agonist activity were further characterized
by dose–response relationships. The rank order of potency
for EXP-1was, TACA>GABA>DAVA>ZAPA> isoguvacine>
muscimol > β-alanine (Figure 2A, Table 1). The rank efficacy
order for EXP-1 was GABA > DAVA > TACA >muscimol >
ZAPA > β-alanine > isoguvacine (Figure 2B, Table 1). TACA
was as potent as GABA and demonstrated strong partial
Figure 2
EXP-1 is differentially activated by GABA agonists. (A) Dose–response curves comparing the responses of each agonist tested normalized to max-
imal GABA responses (3 mM) for EXP-1. Oocytes were voltage clamped at 60 mV, and agonists were bath applied in series (1–3000 μM) for 5 s.
Due to its low potency, β-alanine was applied in series at higher concentrations (3–300 mM). Each data point represents the mean ± SEM with
n ≥ 10 and N = 4. (B) Bar graph illustrating the efficacy of compounds tested relative to maximal GABA responses (3 mM). Each bar represents
the mean ± SEM with n ≥ 10. n.s, not significant (P ≥ 0.05), *P ≤ 0.05; significantly different from GABA; one-way ANOVA, Holm–Sidak post hoc
test. (C) Representative current responses from an EXP-1 expressing oocyte with each compound tested in series at maximal dose (3 mM;
β-alanine = 300 mM). Scale bar = 1 μA, 10 s.
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agonist activity at EXP-1. DAVA was the only compound that
showed full agonist activity at EXP-1 but was slightly less
potent than GABA. All tested agonists produced fast-
desensitizing currents that were similar to those elicited by
GABA (Figure 2C). For LGC-35, the rank order of potency
was similar to EXP-1, GABA > TACA > ZAPA > DAVA >
Figure 3
LGC-35 is differentially activated by GABA agonists. (A) Dose–response curves comparing the responses of each agonist tested relative to maximal
GABA responses (3 mM) for LGC-35. Oocytes were voltage clamped at60 mV, and agonists were bath applied in series (1–3000 μM) to plateau.
Due its low potency, β-alanine was applied in series (3–300 mM). Each data point represents the mean ± SEM with n ≥ 7 and N = 3. (B) Bar graph
illustrating the efficacy of compounds tested relative to maximal GABA responses (3 mM). Each bar represents the mean ± SEMwith n ≥ 7. n.s, not
significant (P ≥ 0.05), *P ≤ 0.05; significantly different from GABA; one-way ANOVA, Holm–Sidak post hoc; (C) Representative current responses
from an LGC-35 expressing oocyte with each compound tested in series at maximal dose (3 mM; β-alanine = 300 mM). Scale bar =1 μA, 30 s.
Table 1
EC50, Hill slope and maximal current response efficacy for agonists at EXP-1 and LGC-35 receptors
Compound
EXP-1 LGC-35
EC50 (μM) Efficacy Hill n EC50 (μM) Efficacy Hill n
GABA 21 ± 0.69 100 0.91 ± 0.06 15 17 ± 0.71 100 2.1 ± 0.10 12
Muscimol 250 ± 22 79 1.2 ± 0.16 11 348 ± 17 62 2.1 ± 0.32 8
TACA 20 ± 2 84 1.7 ± 0.19 11 63 ± 3 100 1.9 ± 0.11 8
DAVA 31 ± 6 95 0.99 ± 0.12 11 142 ± 8 83 1.7 ± 0.03 7
Isoguvacine 155 ± 8 32 2.5 ± 0.53 10 316 ± 9 17 2.9 ± 0.21 7
β-alanine 26 074 ± 2739 55 1.4 ± 0.10 11 37 275 ± 1058 44 1.7 ± 0.08 11
ZAPA 51 ± 4 56 1.4 ± 0.07 12 86 ± 6 100 2.1 ± 0.12 10
Agonist activity at EXP-1 and LGC-35. EC50 (μM), efficacy (% maximal GABA), Hill slope and replicate values (n) are shown as mean ± SEM.
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isoguvacine >muscimol> β-alanine (Figure 3A, Table 1). The
rank order of efficacy for LGC-35 was GABA, TACA,
ZAPA > DAVA > muscimol > β-alanine > isoguvacine
(Figure 3B, Table 1). Maximal agonist concentrations pro-
duced slow-desensitizing currents that were similar to GABA
responses (Figure 3C). The agonist profile of LGC-35 differed
from that of EXP-1 in that both TACA and ZAPA showed full
agonist activity, but their potencies were threefold and five-
fold decreased compared with GABA (Table 1). Taken to-
gether, these data demonstrate that the agonist profiles of
EXP-1 and LGC-35 more closely resemble GABAA-ρ receptors.
Compared with inhibitory nematode UNC-49 GABA re-
ceptors, EXP-1 and LGC-35 exhibit a unique agonist profile.
First, IMA (94% efficacy) and isonipecotic acid (81% efficacy)
are full and strong partial agonists at UNC-49, respectively,
but fail to activate either EXP-1 and LGC-35 (Kaji et al.,
2015). Second, isoguvacine is a strong partial agonist at
UNC-49 (86% efficacy) but a very weak partial agonist at
EXP-1 and LGC-35 (Table 1). Third, DAVA is a very weak par-
tial agonist at UNC-49 (31% efficacy) but is a full agonist at
EXP-1 and strong partial agonist at LGC-35 (Table 1). Fourth,
ZAPA is an extremely weak partial agonist at UNC-49 (11%
efficacy) (Kaji et al., 2015) but exhibits differential activity as
a partial agonist at EXP-1 (56% efficacy) and full agonist at
LGC-35. Together, these data suggest that excitatory and
inhibitory GABA neurotransmission in C. elegans may be
selectively activated using distinct GABA mimetics.
Antagonist profiling of EXP-1 and LGC-35
EXP-1 is highly resistant to the orthosteric competitive
GABAA antagonist bicuculline and the pore blocker picro-
toxin (Beg and Jorgensen, 2003). The pore domain of EXP-1
is functionally analogous to the cation-conducting members
of the ‘Cys-loop’ family, yet EXP-1 is also highly resistant to
the use-dependent nicotinic acetylcholine receptor blocker
mecamylamine. Co-application of GABA (10 μM) with in-
creasing concentrations of bicuculline, picrotoxin and meca-
mylamine corroborated previous data showing that EXP-1 is
strongly resistant to these classical antagonists (Figure 4
A–C). As the agonist profile of EXP-1 and LGC-35 more
closely resembles GABAA-ρ receptors, we tested the inhibitory
effects of the selective and competitive GABAA-ρ antagonist
TPMPA. Current amplitudes of GABA (10 μM) were dose-
Figure 4
EXP-1 is resistant to ionotropic GABA receptor antagonists. (A) Inhibitor dose–response curves were generated by applying GABA (10 μM) alone
followed by GABA plus increasing concentrations of antagonist (10 μM GABA + 1–1000 μM antagonist). TPMPA was the only compound that
potently inhibited EXP-1 GABA-induced currents (IC50 = 172 ± 7 μM). Responses were normalized to maximal GABA (10 μM) responses. Each data
point represents the mean ± SEM with n ≥ 8 and N = 3. (B) Bar graph illustrating the efficacy of compounds tested (10 μM GABA + 1 mM antag-
onist) relative to maximal GABA only responses (10 μM). Each bar represents the mean ± SEM with n ≥ 8 and N = 3. (C) Representative current
responses from an EXP-1 expressing oocyte with each compound tested in series at maximal dose (10 μM GABA + 1 mM antagonist). GABA re-
sponsiveness fully recovers (2 min wash) after complete TPMPA inhibition. Scale bar = 0.5 μA, 10 s.
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dependently inhibited by increasing concentrations of
TPMPA (Figure 4, IC50 = 172 ± 7 μM). THIP (gaboxadol) is
widely used as a high efficacy partial agonist at GABAA recep-
tors but exhibits antagonist activity at GABAA-ρ receptors
(Krogsgaard-Larsen et al., 2002). The lack of agonist activity
at EXP-1 and LGC-35 suggested that THIP may be an antago-
nist at these receptors. Application of increasing concentra-
tions of THIP dose-dependently decreased GABA currents,
but inhibition was no greater than bicuculline, picrotoxin
or mecamylamine, which all reduced GABA (10 μM) currents
by ~50% (Figure 4A–C).
LGC-35 was recently demonstrated to be an excitatory
GABA receptor in C. elegans, but the receptor’s pharmacolog-
ical profile remains completely unknown (Jobson et al.,
2015). We tested a panel of antagonists against LGC-35. The
antagonist profile of LGC-35 was similar to EXP-1 with some
notable differences. First, bicuculline, picrotoxin and THIP all
showed relatively similar antagonist activity at LGC-35, with
each compound capable of blocking GABA (10 μM) currents
by ~75% (Figure 5A, B). Compared with EXP-1, these
antagonists were not only more efficacious at blocking
GABA-induced currents but also exhibited greater potency.
Interestingly, mecamylamine showed no difference in its
antagonism at LGC-35, compared with EXP-1. To further
probe the pore-forming domain, we applied known pore
blockers of ionotropic GABA receptors to EXP-1 and
LGC-35 expressing oocytes. The insecticide dieldrin, β-lactam
antibiotic penicillin G, and widely used pro-convulsant pen-
tylenetetrazol all failed to block GABA-induced currents (data
not shown). Taken together, these data suggest that the
nearly identical M2 pore forming domain (85% identity,
100% similarity) shared between EXP-1 and LGC-35 is dis-
tantly related to other anion- and cation-conducting pores
of the ‘Cys-loop’ superfamily. Lastly, TPMPA was the only
compound tested that was able to fully block LGC-35
GABA-induced currents (Figure 5, IC50 = 61 ± 4 μM). From a
pharmacological perspective, the antagonist and agonist pro-
files suggest that EXP-1 and LGC-35 more closely resemble
the GABAA-ρ receptor subfamily.
Homology modelling of EXP-1 and LGC-35
The crystal structure of the human homopentameric β3
GABAA receptor was used as a template for homology model-
ling of the nematode EXP-1 and LGC-35 receptors (Miller and
Aricescu, 2014). GABA docked into the highly conserved
aromatic-rich binding pocket that is located between the
‘principal’ and ‘complementary’ subunit interface (Figure 6
A, E). In EXP-1, the amino group of GABA is positioned to hy-
drogen bondwith the side chain of Glu250 (loop B), the back-
bone carbonyl groups of Ser251 and Tyr252 (both loop B),
and have potential cation–π interactions with Tyr252 and
Tyr300 (loop C), similar to the binding mode observed in
the human GABA receptor (Figures 1A, 6A) (Miller and
Aricescu, 2014). GABA also docked in a highly conserved
manner in the LGC-35 model (Figures 1A, 6E). In both
models, the agonists TACA, DAVA and β-alanine docked with
their amine nitrogen in a similar pose to that observed for
GABA (Figure 6B–D, F–H). The binding energies (ΔG) for
GABA, TACA, DAVA and β-alanine were 4.2, 4.4, 4.4
and 3.5 kcal·mol1 for EXP-1 and 4.3, 4.4, 4.8 and
3.6 kcal·mol1 for LGC-35 respectively. One of the major
differences between the models is that a lysine residue,
Lys245 (loop F), is located in the proximity of ligands in
LGC-35, as opposed to a Glu272 (loop F) in the corresponding
position in EXP-1 (Figures 1A, 6E–H). The resulting charge re-
versal orients the ligand carboxyl group in closer proximity to
Lys245, as opposed to Arg153 (loop D) in EXP-1. Finally, com-
pared with the other agonists, β-alanine fails to extend across
the binding pocket, losing energetically favourable electro-
static interactions with ‘complementary’ subunit residues,
which is likely to reduce binding energy and contributes to
the weak partial agonist activity.
Neurosteroids do not modulate EXP-1 and
LGC-35
Neuroactive steroids, metabolites of the stress hormone
corticosterone and progesterone, can potently modulate
(low nanomolar concentration) or directly activate (micro-
molar concentration) vertebrate and invertebrate ionotropic
GABA receptors (Lambert et al., 2003). The endogenous
neurosteroid pregnanalone and the synthetic neurosteroid
alphaxalone potently potentiate mammalian GABAA recep-
tors. In contrast, vertebrate GABAA-ρ receptors are differen-
tially modulated by these neurosteroids, where alphaxalone
potentiates, but pregnanalone inhibits GABA-induced cur-
rents (Morris et al., 1999). We tested if neurosteroids can
modulate or directly activate EXP-1 and LGC-35. In the ab-
sence of GABA, application of high concentrations of
pregnanalone (30 μM) or alphaxalone (100 μM) failed to di-
rectly activate either receptor, demonstrating that these
neurosteroids have no agonist-like activity at EXP-1 or LGC-
35. However, co-application of increasing concentrations of
alphaxalone and pregnanalone with GABA weakly inhibited
EXP-1 and LGC-35 GABA-induced currents, when compared
with GABA alone (Figure 7A, B). Although weak, the
neurosteroid inhibition of LGC-35 was markedly increased
compared with EXP-1 (Figure 7C, D). Like EXP-1 and LGC-
35, the inhibitory C. elegans GABAA receptor UNC-49 is only
slightly inhibited by alphaxalone but can be completely
blocked by pregnanalone (Bamber et al., 2003). These data
demonstrate that the site for neuroactive modulation is likely
to be unique in that EXP-1 and LGC-35 receptors resemble
neither the modulatory properties of GABAA, GABAA-ρ or
nematode UNC-49 receptors.
LGC-35 is selectively potentiated by ethanol
Anaesthetic drugs, including ethanol, can modulate cellular
and network signal transduction by altering the function of
a wide variety of ion channels, transporters, receptors and en-
zymes (Lobo and Harris, 2008). However, the contribution of
these molecular targets to the intoxicating and behavioural
effects of ethanol remain unclear. GABAA receptors are
thought to be key targets of ethanol action in the brain, and
subunit composition is a critical determinant that mediates
the potentiating effect of alcohol in heteropentameric
GABAA receptors (Mihic et al., 1997). In contrast, the single
subunit homopentameric ρ1 receptor is inhibited by alcohol.
At a molecular level, key residues in transmembrane domains
2 and 3 (M2 and M3) have been shown to mediate the poten-
tiating or inhibitory effects of alcohol in GABAA versus
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788 British Journal of Pharmacology (2017) 174 781–795
GABAA-ρ receptors respectively. The 150 serine residue (S270)
in M2 and alanine residue (A291) in M3 of the α1 GABAA re-
ceptor subunit were shown to critically regulate ethanol po-
tentiation (Figure 8F) (Mihic et al., 1997; Ueno et al., 1999).
In the ρ1 receptor, the analogous isoleucine residue in M2
(I307) and asparagine residue in M3 (W328) confer resistance
against the potentiating effect of ethanol (Figure 8F) (Mihic
et al., 1997; Borghese et al., 2016). We used these distinct
structural properties to determine if EXP-1 and LGC-35 are
modulated by ethanol. Ethanol did not significantly potenti-
ate or inhibit EXP-1 current responses (expressed as % change
of 10 μM GABA responses) at any concentration tested
Figure 5
LGC-35 is sensitive to ionotropic GABA receptor antagonists. (A) Inhibitor dose–response curves were generated by applying GABA (10 μM) alone
followed by GABA plus increasing concentrations of antagonist (10 μMGABA + 1–1000 μM antagonist). TPMPA was the most potent inhibitor of
LGC-35 GABA-induced current (IC50 = 61 ± 4 μM). Responses were normalized to maximal GABA only responses. Each data point represents the
mean ± SEMwith n ≥ 7 andN = 3. (B) Bar graph illustrating the efficacy of compounds tested (10 μMGABA + 1mM antagonist) relative tomaximal
GABA only responses (10 μM). Each bar represents the mean ± SEM with n ≥ 7 and N = 3. (C) Representative current responses of individual LGC-
35 expressing oocytes. GABA (10 μM) was applied until a steady-state non-desensitizing plateau was reached. Subsequently, increasing concen-
trations of antagonist (1–1000 μM antagonist) were applied in series in the presence of constant GABA (10 μM). The grey bars above each trace
denote GABA application, and the coloured bars illustrate antagonist concentration co-applications. GABA responsiveness fully recovers after the
highest antagonist concentration block. Scale bar = 1 μA, 30 s.
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Figure 6
Homology models of EXP-1 and LGC-35. (A–D) Molecular modelling of the binding modes of: (A) GABA, (B) TACA, (C) DAVA and (D) β-alanine in
the homology model of EXP-1. The homology model of EXP-1 was constructed based on the crystal structure of human GABA receptor, and the
ligands were docked to the model with Autodock Vina software as described in the section. Ligands are coloured green with oxygen labelled red
and nitrogen blue. Dotted lines represent potential hydrogen bonds between ligand and receptor residues. Solid light grey line represents poten-
tial electrostatic interactions of the ligand carboxyl group with Arg126. Labelled distances are in angstroms. Unlabelled potential hydrogen bonds
were less than 3.1 Å. Residues were numbered beginning at the start methionine. (E–H) Molecular modelling of the binding modes of: (A) GABA,
(B) TACA, (C) DAVA and (D) β-alanine in the homology model of LGC-35. The homology model of EXP-1 was constructed based on the crystal
structure of human GABA receptor, and the ligands were docked to the model with Autodock Vina software as described in the section. Ligands
are coloured green with oxygen labelled red and nitrogen blue. Dotted lines represent potential hydrogen bonds between ligand and receptor
residues. Solid light grey line represents potential electrostatic interactions of the ligand carboxyl group with Lys 245. Labelled distances are in
angstroms. Unlabelled potential hydrogen bonds were less than 3.2 Å. Residues were numbered beginning at the start methionine.
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(Figure 8A). Although lower doses of ethanol (10 and 30 mM)
did not significantly modulate LGC-35 current responses,
higher doses (100, 200 and 500 mM) did significantly poten-
tiate LGC-35 current response amplitudes (Figure 8C). Step-
wise ramps of increasing concentrations demonstrate the
potentiating effect of alcohol in the presence of constant
GABA exposure (Figure 8E).
Sequence alignments reveal that EXP-1 contains an iden-
tical isoleucine at the 150 position (I357), which is a critical
determinant of alcohol resistance in the ρ1 receptor
(Figure 8E). Interestingly, LGC-35 has a similar leucine at
the 150 position (L330), yet the receptor is significantly po-
tentiated by high concentrations of ethanol (Figure 8E). Both
receptors contain a glycine residue in the M3 domain, which
is similar to the alanine residue (A291) present in the α1
GABAA receptor subunit that confers alcohol sensitivity but
markedly different from the asparagine residue (W328) in
the ρ1 subunit that confers alcohol resistance (Figure 8E). Al-
though the potentiating concentrations of ethanol are not
likely to be physiologically relevant, these data reveal that
the differential effects of ethanol on EXP-1 and LGC-35
GABA-induced current are likely to be distinct from the previ-
ously identified residues that confer alcohol sensitivity to
ionotropic GABA receptors. Together, these data may provide
new insights into molecular determinants that contribute to
alcohol modulation in ionotropic GABA receptors.
Discussion
EXP-1 and LGC-35 compose the excitatory GABA receptor
family in C. elegans and play important roles in distinct neu-
romuscular contractions that regulate defecation and loco-
motion respectively (Beg and Jorgensen, 2003; Jobson et al.,
2015). Since their initial cloning and characterization, these
receptors have been loosely classified as belonging to the
GABAA receptor subtype family. Using a broad panel of phar-
macological agonists, antagonists and modulators, we dem-
onstrate this unique receptor family more closely resembles
the GABAA-ρ family. We discuss our findings in regard to the
structure, function and pharmacology of ‘Cys-loop’ ligand-
gated ion channels.
GABA pharmacophores suggest EXP-1 and
LGC-35 are activated by conformationally
extended agonists
Decades of elegant research has demonstrated that vertebrate
GABAA and GABAA-ρ receptors are differentially sensitive to
Figure 7
EXP-1 and LGC-35 are not modulated by neurosteroids. (A) EXP-1 neurosteroid dose–response curves were generated by applying GABA (10 μM)
alone or GABA plus increasing concentrations of neurosteroids (10 μMGABA + alphaxalone = 1, 3, 10 and 30 μM; pregnanalone = 1, 3, 10, 20 and
30 μM). Responses were normalized to maximal GABA only responses. Each data point represents the mean ± SEM with n ≥ 6 and N = 2. (B) LGC-
35 neurosteroid dose–response curves were generated by applying GABA (10 μM) alone or with increasing concentrations of neurosteroids
(alphaxalone = 1, 3, 10, 30 and 100 μM; pregnanalone = 1, 3, 10, 20 and 30 μM). Responses were normalized to maximal GABA only responses.
Each data point represents the mean ± SEM with n ≥ 7 and N = 2. (C) Comparative sequence alignment of transmembrane domain (M1),
highlighting key residues that confer differential neurosteroid sensitivity (blue) and resistance (red) in the human α1 GABAA subunit and fly
RDL subunit respectively. EXP-1 and LGC-35 contain a similar valine and an identical asparagine present in the neurosteroid resistant RDL recep-
tor. Dark grey shading marks amino acid identity and light grey shading identifies similarity.
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Figure 8
LGC-35 is selectively potentiated by ethanol. (A) EXP-1 is neither significantly potentiated nor inhibited by ethanol. Current responses of co-ap-
plied ethanol (10 μMGABA + 10–500 mM ethanol) were normalized relative to maximal GABA only responses (10 μM). For each oocyte, an initial
stable GABA response was first achieved. Subsequently, co-application of 10 μM GABA + increasing concentrations of ethanol were bath applied
for 5 s, followed by a 2 min wash. Each bar represents the mean ± SEM with n ≥ 8 and N = 3. (B) Representative current responses from an EXP-1
expressing oocyte with co-application of increasing concentrations of ethanol. Scale bar = 0.5 μA, 10 s. (C) LGC-35 is potentiated by high
concentrations of ethanol. Current responses of co-applied ethanol (10 μM GABA + 10–500 mM ethanol) were normalized relative to maximal
GABA only responses (10 μM). For each oocyte, an initial stable GABA response was first achieved. Subsequently, co-application of 10 μM
GABA + increasing concentrations of ethanol were bath applied until a plateau was reached, followed by a 2 min wash. LGC-35 current responses
are significantly potentiated by high concentrations of ethanol (100–500 mM). Each bar represents the mean ± SEMwith n ≥ 8 and N = 3. n.s, not
significant (P ≥ 0.05), *P< 0.05; One-way ANOVA with Holm–Sidak post hoc test. (D) Representative current responses from an LGC-35 expressing
oocyte with co-application of increasing concentrations of ethanol. Note, GABA responsiveness is unchanged compared with initial GABA-only
responses after increasing series of ethanol exposure. Scale bar = 0.5 μA, 30 s. (E) Representative current responses from an LGC-35 expressing
oocyte. GABA (10 μM) was applied until a steady-state non-desensitizing plateau was reached. Subsequently, increasing concentrations of etha-
nol (100–500 mM) were applied in series in the presence of constant GABA (10 μM). The grey bars above each trace denote constant GABA ex-
posure, and the coloured bars illustrate ethanol concentration co-applications. Scale bar = 1 μA, 60 s. (F) Comparative sequence alignment of
transmembrane domains 2 and 3 (M2 and M3), highlighting key residues that confer differential ethanol sensitivity (blue) and resistance (red)
in the human α1 and ρ1 receptor subunits respectively. Dark grey shading marks amino acid identity, and light grey shading shows similarity.
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conformationally restricted analogues of GABA (Krogsgaard-
Larsen et al., 2002; Johnston, 2005; Johnston et al., 2010).
Specifically, GABAA receptors tend to be preferentially acti-
vated by partially folded forms of GABA; whereas, GABAA-ρ
receptors are activated by extended or near planar forms of
GABA. Using a collection of conformationally restricted ana-
logues, we conclude that both EXP-1 and LGC-35 more
closely resemble the GABAA-ρ family.We draw several conclu-
sions based on our data. First, the homo-oligomeric assembly
of EXP-1 and LGC-35 supports their classification in the
GABAA-ρ family. Unlike GABAA-ρ receptors, the vast majority
of GABAA receptors are hetero-oligomers composed of three
distinct subunits, with the (α1)2(β2)2(γ2)1 combination being
themost abundant in the human brain (Sigel and Steinmann,
2012). Moreover, EXP-1 and LGC-35 are not expressed in the
same cells in vivo further supporting that these receptors do
not act as hetero-oligomers (Beg and Jorgensen, 2003; Jobson
et al., 2015). Second, dose–response relationships reveal that
most of the partially folded GABA analogues tested either
showed no agonist activity (nipecotic acid, IMA and P4S) or
were weak partial agonists (muscimol and isoguvacine) at
both EXP-1 and LGC-35. In contrast, the extended and non-
aromatic analogues (TACA and DAVA) showed both higher
potency and efficacy at EXP-1 and LGC-35. Third, carbon
backbone length appears to be a key determinant of agonist
potency and efficacy at EXP-1 and LGC-35. More specifically,
increasing the carbon backbone length by one (DAVA) right
shifts the potency in both EXP-1 and LGC-35 and decreases
efficacy in LGC-35, but not in EXP-1. Reduction of the carbon
backbone length by one (β-alanine) severely reduced both po-
tency and efficacy, and reduction by two carbons (glycine)
yields no activity at either receptor. Supporting these observa-
tions, TACA, which shares the same carbon backbone length
as GABA, was the most potent and efficacious compound
tested at both receptors. A double bond between carbons 2
and 3 hold TACA in an extended conformation, supporting
a model in which EXP-1 and LGC-35 are preferentially acti-
vated by extended ligands as opposed to folded forms.
Fourth, although the pharmacological profile of EXP-1 and
LGC-35 shares a resemblance to GABAA-ρ receptors, there
are notable exceptions that set these receptors apart as a fam-
ily. ZAPA is a potent and full agonist at GABAA receptors but is
an antagonist at GABAA-ρ receptors. We demonstrate that
ZAPA is an agonist at EXP-1 and LGC-35 and not an antago-
nist as would have been predicted based on our pharmacolog-
ical profiling. These data demonstrate that EXP-1 and LGC-35
exhibit a unique and hybrid pharmacological profile. Com-
parison of the ligand-binding loops from EXP-1 and LGC-35
with ρ1 subunit demonstrates high conservation in residues
implicated in the orthosteric binding site. Furthermore,
EXP-1 and LGC-35 contain a single non-conserved amino
acid difference in loop C. Whether or not this single change
accounts for the differential agonist activity at EXP-1 and
LGC-35 remains to be determined.
EXP-1 and LGC-35 exhibit hybrid antagonist
pharmacology
High affinity for GABA, bicuculline resistance and picrotoxin
sensitivity are characteristic features of GABAA-ρ receptors
(Johnston et al., 2010). From a pharmacological perspective,
the agonist data suggest that EXP-1 and LGC-35 more closely
resemble GABAA-ρ receptors. In accordance with the agonist
profile, both receptors were highly resistant to bicuculline as
expected but were also resistant to picrotoxin block. We pre-
viously characterized the molecular mechanisms of ion selec-
tivity in the pore forming domain of both EXP-1 and LGC-35
(Beg and Jorgensen, 2003; Jobson et al., 2015). Here, we inves-
tigated this unusual pore domain using a panel of well-
characterized channel blockers at ‘Cys-loop’ ligand-gated
ion channels. We failed to identify a single compound
thought to act via pore blockade that could effectively inhibit
GABA-induced currents. These data emphasize that the pore-
forming domain of EXP-1 and LGC-35 is highly divergent
from any known GABAA or GABAA-ρ receptors.
Supporting their GABAA-ρ-like characteristics, both EXP-1
and LGC-35 were dose-dependently inhibited by the selective
GABAA-ρ antagonist TPMPA. Furthermore, THIP, which dif-
ferentially acts as a GABAA receptor agonist but a GABAA-ρ an-
tagonist, exhibited inhibitory activity at EXP-1 and LGC-35.
These data suggest that EXP-1 and LGC-35 more closely re-
semble GABAA-ρ receptors, although they exhibit a hybrid
pharmacology that is not observed in either GABAA or
GABAA-ρ receptors.
Molecular profiling of neurosteroid resistance
GABAA receptors can be potently modulated by endogenous
neurosteroids (Belelli and Lambert, 2005). Low nanomolar
concentrations can potentiate GABA-induced currents (Zhu
and Vicini, 1997; Belelli and Herd, 2003; Stell et al., 2003),
and micromolar concentrations can directly activate recep-
tors (Majewska et al., 1986). Pregnanalone, an endogenous
progesterone metabolite, and the synthetic neurosteroid
alphaxalone strongly enhance GABAA-induced currents. In
contrast, GABAA-ρ receptors are differentially modulated by
neurosteroids, where pregnanalone inhibits and alphaxalone
potentiates ρ1 receptors (Morris et al., 1999). In comparison
to GABAA receptors, which are enhanced in the nanomolar
range, neurosteroid modulation of GABAA-ρ receptors occur
in the high micromolar range. We found that pregnanalone
and alphaxalone exhibited almost no modulatory activity at
EXP-1 (Figure 7A) but weakly inhibited LGC-35 only in the
high micromolar range (Figure 7B). Previous studies have
shown that the inhibitory nematode GABA receptor UNC-
49 is strongly inhibited by pregnanalone but is not modu-
lated by alphaxalone (Bamber et al., 2003); whereas, the fly
GABA receptor RDL is weakly potentiated by neurosteroids
(Chen et al., 1994). Chimeric studies using fly RDL andmouse
α1 subunits identified two discrete residues in transmem-
brane domain 1 that differentially contribute to direct
neurosteroid activation and potentiation of GABA receptors
(Hosie et al., 2006). In the α1 subunit, a threonine (T236) in
the transmembrane domain 1 was shown to be a major deter-
minant for direct neurosteroid activation (Figure 7C). Substi-
tution with an isoleucine present in RDL (T236I) markedly
attenuated direct neurosteroid receptor activation without al-
tering potentiation. Using the same strategy, a glutamine
(Q241) in transmembrane 1 was found to be critically impor-
tant for neurosteroid potentiation (Figure 7C). Substitution
with an asparagine present in RDL at this position (Q241W)
ablated neurosteroid potentiation. Comparative sequence
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alignments with RDL reveal that EXP-1 and LGC-35 contain a
similar valine at that analogous position 236 and an identical
asparagine at analogous position 241, which are likely to ac-
count for the lack of neurosteroid activation or potentiation
(Figure 7C). Taken together, these data demonstrate that
EXP-1 and LGC-35 exhibit a neurosteroid profile that does
not resemble vertebrate GABAA or GABAA-ρ receptors, or the
inhibitory nematode GABA receptor UNC-49.
Does LGC-35 play a role in ethanol-mediated
behaviours in C. elegans?
Ethanol produces profound behavioural effects in both
humans and C. elegans at equivalent concentrations
(McIntire, 2010). However, the relevant molecular targets
and biochemical pathways that mediate these effects remain
unclear, as ethanol modulates a wide variety of receptors,
ion channels and enzymes. The differential functional effect
of ethanol on EXP-1 and LGC-35 is intriguing given the al-
most identical sequence conservation shared between the
two proteins. Ethanol had no effect on EXP-1 GABA-induced
currents but significantly potentiated LGC-35 current re-
sponses at higher doses (100–500 mM). From a behavioural
perspective, acute exposure to ethanol produces dose-
dependent changes in locomotor behaviours in C. elegans
(McIntire, 2010). Increasing concentrations of ethanol flat-
ten the amplitude of body-bending and decreases speed of
movement (Davies et al., 2003). We recently reported that
LGC-35 regulates locomotor body bending and movement
speed in C. elegans (Jobson et al., 2015). Specifically, deletion
of LGC-35 results in exaggerated body bending and increases
animals’ speed of movement. The specific ethanol potentia-
tion of LGC-35 coupled with our cellular, molecular and be-
havioural data suggests that LGC-35 may be a relevant
effector of ethanol’s action in C. elegans; however, this re-
mains to be tested.
In conclusion, the results from our studies expand the
molecular repertoire for studying ionotropic GABA receptor
structure–function relationships. The unique pharmacologi-
cal profiles of EXP-1 and LGC-35 provide novel frameworks
to differentially probe agonists, antagonists and allosteric
modulation at GABAA and GABAA-ρ receptors. Furthermore,
the homo-oligomeric assembly simplifies identifying critical
amino acid residues and motifs, as the binding interfaces
and ligand recognition sites are identical in each receptor
complex. The highly conserved ligand-binding loops suggest
that the orthosteric GABA binding site is similar to vertebrate
GABA receptors, but the hybrid pharmacology and differen-
tial sensitivities of EXP-1 and LGC-35 may provide a new tool
for anthelmintic drug discovery and for the rationale design
of GABA mimetics.
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